rheumatic diseases

Summary

Summary: Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.

Top Publications

  1. pmc Cartilage homeostasis in health and rheumatic diseases
    Mary B Goldring
    Research Division, Hospital for Special Surgery, Affiliated with Weill College of Medicine of Cornell University, New York, NY 10021, USA
    Arthritis Res Ther 11:224. 2009
  2. ncbi Surveillance of systemic autoimmune rheumatic diseases using administrative data
    S Bernatsky
    Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, 687 Pine Avenue West, V Building, V2 09, Montreal, QC H3A 1A1, Canada
    Rheumatol Int 31:549-54. 2011
  3. ncbi Epigenetic alterations in autoimmune rheumatic diseases
    Esteban Ballestar
    Bellvitge Biomedical Research Institute, Barcelona, Spain
    Nat Rev Rheumatol 7:263-71. 2011
  4. ncbi What's new in our understanding of the role of adipokines in rheumatic diseases?
    Rodolfo Gomez
    SERGAS, Santiago University Clinical Hospital, Research Laboratory, Institute of Medical Research, Travesía de la Choupana, Santiago de Compostela, Spain
    Nat Rev Rheumatol 7:528-36. 2011
  5. ncbi Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there?
    Antonella Fioravanti
    Rheumatology Unit, Department of Clinical Medicine and Immunology, University of Siena, Viale Bracci 1, 53100 Siena, Italy
    Rheumatol Int 31:1-8. 2011
  6. ncbi Accelerated atherosclerosis in autoimmune rheumatic diseases
    Yehuda Shoenfeld
    Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Circulation 112:3337-47. 2005
  7. ncbi Contemporary concepts of inflammation, damage and repair in rheumatic diseases
    Frank P Luyten
    University Hospitals Leuven, Division of Rheumatology, Herestraat 49, B 3000 Leuven, Belgium
    Best Pract Res Clin Rheumatol 20:829-48. 2006
  8. ncbi Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies
    Eamonn S Molloy
    St Vincent s University Hospital, Elm Park, Dublin, Ireland
    Arthritis Rheum 64:3043-51. 2012
  9. pmc Application of the health assessment questionnaire disability index to various rheumatic diseases
    Maaike M van Groen
    Institute for Behavioral Research, Faculty of Behavioral Sciences, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands
    Qual Life Res 19:1255-63. 2010
  10. ncbi Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases
    Myoung Hee Kim
    Department of Preventive Medicine, Eulji University School of Medicine, Daejeon, Republic of Korea
    Qual Life Res 14:1401-6. 2005

Detail Information

Publications302 found, 100 shown here

  1. pmc Cartilage homeostasis in health and rheumatic diseases
    Mary B Goldring
    Research Division, Hospital for Special Surgery, Affiliated with Weill College of Medicine of Cornell University, New York, NY 10021, USA
    Arthritis Res Ther 11:224. 2009
    ..This review will cover current knowledge about the specific cellular and biochemical mechanisms that regulate cartilage homeostasis and pathology...
  2. ncbi Surveillance of systemic autoimmune rheumatic diseases using administrative data
    S Bernatsky
    Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, 687 Pine Avenue West, V Building, V2 09, Montreal, QC H3A 1A1, Canada
    Rheumatol Int 31:549-54. 2011
    There is growing interest in developing tools and methods for the surveillance of chronic rheumatic diseases, using existing resources such as administrative health databases...
  3. ncbi Epigenetic alterations in autoimmune rheumatic diseases
    Esteban Ballestar
    Bellvitge Biomedical Research Institute, Barcelona, Spain
    Nat Rev Rheumatol 7:263-71. 2011
    The potential roles of epigenetic alterations in the pathogenesis of autoimmune rheumatic diseases are raising great expectations among clinicians and researchers...
  4. ncbi What's new in our understanding of the role of adipokines in rheumatic diseases?
    Rodolfo Gomez
    SERGAS, Santiago University Clinical Hospital, Research Laboratory, Institute of Medical Research, Travesía de la Choupana, Santiago de Compostela, Spain
    Nat Rev Rheumatol 7:528-36. 2011
    ..a plethora of immune and inflammatory mediators that are involved in numerous diseases, including not only rheumatic diseases such as rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus, but also cardiovascular and ..
  5. ncbi Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there?
    Antonella Fioravanti
    Rheumatology Unit, Department of Clinical Medicine and Immunology, University of Siena, Viale Bracci 1, 53100 Siena, Italy
    Rheumatol Int 31:1-8. 2011
    Spa therapy represents a popular treatment for many rheumatic diseases. The mechanisms by which immersion in mineral or thermal water or the application of mud alleviates suffering in rheumatic diseases are not fully understood...
  6. ncbi Accelerated atherosclerosis in autoimmune rheumatic diseases
    Yehuda Shoenfeld
    Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Circulation 112:3337-47. 2005
  7. ncbi Contemporary concepts of inflammation, damage and repair in rheumatic diseases
    Frank P Luyten
    University Hospitals Leuven, Division of Rheumatology, Herestraat 49, B 3000 Leuven, Belgium
    Best Pract Res Clin Rheumatol 20:829-48. 2006
    ..Understanding the molecular networks of joint homeostasis, repair and remodelling will be required to achieve this goal. Defining and validating clinical outcomes evaluating remission remain a challenge...
  8. ncbi Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies
    Eamonn S Molloy
    St Vincent s University Hospital, Elm Park, Dublin, Ireland
    Arthritis Rheum 64:3043-51. 2012
    To evaluate the association of progressive multifocal leukoencephalopathy (PML) with immunosuppressive therapy for autoimmune rheumatic diseases (ARDs).
  9. pmc Application of the health assessment questionnaire disability index to various rheumatic diseases
    Maaike M van Groen
    Institute for Behavioral Research, Faculty of Behavioral Sciences, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands
    Qual Life Res 19:1255-63. 2010
    ..Questionnaire Disability Index (HAQ-DI) can serve as a generic instrument for measuring disability across different rheumatic diseases and to propose a scoring method based on item response theory (IRT) modeling to support this goal.
  10. ncbi Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases
    Myoung Hee Kim
    Department of Preventive Medicine, Eulji University School of Medicine, Daejeon, Republic of Korea
    Qual Life Res 14:1401-6. 2005
    ..This study aimed to determine the cross-cultural adaptation and validation of the Korean version of the EQ-5D in rheumatic conditions...
  11. ncbi The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases
    Maurizio Cutolo
    Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy
    Ann N Y Acad Sci 1193:36-42. 2010
    ..In conclusion, estrogens are generally considered as enhancers of cell proliferation and humoral immune response...
  12. ncbi Air pollution in autoimmune rheumatic diseases: a review
    Sylvia C L Farhat
    Environmental Epidemiology Study Group, Laboratory of Experimental Air Pollution, University of São Paulo Faculty of Medical Sciences, Brazil
    Autoimmun Rev 11:14-21. 2011
    ..response and autoimmunity, and it focuses on studies of inhaled pollutants triggering and/or exacerbating rheumatic diseases in cities around the world...
  13. ncbi EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
    S van Assen
    Department of Internal Medicine, Division of Infectious Diseases, University Medical Centre Groningen, AA41 P O Box 30 001, 9700 RB Groningen, The Netherlands
    Ann Rheum Dis 70:414-22. 2011
    To develop evidence-based European League Against Rheumatism (EULAR) recommendations for vaccination in patients with autoimmune inflammatory rheumatic diseases (AIIRD).
  14. ncbi The role of microparticles in the pathogenesis of rheumatic diseases
    Christian Beyer
    Department for Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Nat Rev Rheumatol 6:21-9. 2010
    ..MPs) are small membrane-bound vesicles that are emerging as important elements in the pathogenesis of rheumatic diseases owing to their pleiotropic effects on thrombosis, vascular reactivity, angiogenesis and inflammation...
  15. pmc Blocking interleukin-1 in rheumatic diseases
    Raphaela Goldbach-Mansky
    National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1182:111-23. 2009
    ....
  16. ncbi Vitamin D endocrine system and the immune response in rheumatic diseases
    Maurizio Cutolo
    Research Laboratories and Academic Unit of Clinical Rheumatology, Postgraduate Academic School of Rheumatology, University of Genova, Genova, Italy
    Vitam Horm 86:327-51. 2011
    ....
  17. ncbi Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis
    Mogens Fenger
    Department of Clinical Biochemistry, University Hospital of Copenhagen, Hvidovre, Denmark
    Clin Chem 50:2141-7. 2004
    Antinuclear antibodies (ANAs) are associated with several inflammatory rheumatic diseases. The aim of the present work was to evaluate enzyme immunoassays (EIAs) and compare them with classic immunofluorescent analysis (IFA) for the ..
  18. ncbi Psychometric properties of the RAND-36 among three chronic diseases (multiple sclerosis, rheumatic diseases and COPD) in The Netherlands
    P Moorer
    Northern Centre for Healthcare Research NCH, University of Groningen, The Netherlands
    Qual Life Res 10:637-45. 2001
    ..In this article, psychometric properties both of the total RAND-36 and of its subscales, such as unidimensionality, differential item functioning (DIF or item bias), homogeneity and reliabilities, are examined...
  19. ncbi High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease
    Y Muro
    Division of Connective Tissue Disease and Autoimmunity, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Japan
    Lupus 17:171-6. 2008
    ..Recognizing dense fine speckle patterns in anti-nuclear antibodies tests is, thus, very important for analysis of laboratory results in rheumatology clinics...
  20. ncbi Anti-DFS70 antibodies in 597 healthy hospital workers
    Akihiro Watanabe
    Nagoya University Graduate School of Medicine, Nagoya, Japan
    Arthritis Rheum 50:892-900. 2004
    ..We undertook this study to examine the frequency of anti-DFS70 antibodies in a large number of healthy people...
  21. pmc Rheumatic diseases in China
    Qing Yu Zeng
    Department of Rheumatology, The 1st Affiliated Hospital, Shantou University Medical College, 22 Xinling Road, Shantou, 515041 Guangdong, China
    Arthritis Res Ther 10:R17. 2008
    Epidemiological studies of rheumatic diseases have been conducted during the past 20 years in China. The aim of this study was to clarify prevalence rates of common rheumatic diseases in China.
  22. ncbi Contribution of reactive oxygen species to cartilage degradation in rheumatic diseases: molecular pathways, diagnosis and potential therapeutic strategies
    J Schiller
    Institute of Medical Physics and Biophysics, Medical Department, University of Leipzig, Germany
    Curr Med Chem 10:2123-45. 2003
    ..First, the relevance of rheumatic diseases and potential mechanisms of cartilage degradation are discussed in this review, followed by the description ..
  23. pmc The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases
    Nicole H Kattah
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Immunol Rev 233:126-45. 2010
    ..small nuclear ribonucleoprotein particle (snRNP) is a target of autoreactive B cells and T cells in several rheumatic diseases including systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)...
  24. ncbi The hypothalamic-pituitary-adrenal axis in the pathogenesis of rheumatic diseases
    Leslie J Crofford
    Department of Internal Medicine and Rheumatology, University of Michigan, Room 5510, MSRB I, 1150 W Medical Center Dr, An Arbor, MI 48109 0680, USA
    Endocrinol Metab Clin North Am 31:1-13. 2002
    Many studies have demonstrated altered HPA axis activity in patients with rheumatic diseases. In the case of autoimmune inflammatory diseases, circumstantial evidence suggests that failure of the neuroendocrine-immune regulatory loop may ..
  25. ncbi Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment
    Pal Soltesz
    University of Debrecen Medical and Health Sciences Center, Institute of Medicine, Third Department of Medicine, Angiology and Intensive Care Unit, Debrecen, Hungary
    Autoimmun Rev 10:416-25. 2011
    Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis or other types of vasculopathy leading to increased cardio- and cerebrovascular disease risk...
  26. ncbi EULAR recommendations for vaccination in paediatric patients with rheumatic diseases
    M W Heijstek
    Department of Paediatric Immunology, Wilhelmina Children s Hospital, University Medical Centre Utrecht, Room KC 03 063 0, PO Box 85090, 3508 AB Utrecht, The Netherlands
    Ann Rheum Dis 70:1704-12. 2011
    Evidence-based recommendations for vaccination of paediatric patients with rheumatic diseases (PaedRD) were developed by following the EULAR standardised procedures for guideline development...
  27. ncbi Reduction of job loss in persons with rheumatic diseases receiving vocational rehabilitation: a randomized controlled trial
    Saralynn H Allaire
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Arthritis Rheum 48:3212-8. 2003
    Job loss is a major consequence of rheumatic diseases, and clinicians may refer patients to vocational rehabilitation for help. When provided after job loss, the impact of vocational rehabilitation is short term...
  28. ncbi Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action
    Steven J Katz
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Curr Opin Rheumatol 23:278-81. 2011
    ..Over the past decade, new theories have been proposed in this regard both for rheumatic disease, as well as related conditions...
  29. ncbi Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases
    Henrique A Mariz
    Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Arthritis Rheum 63:191-200. 2011
    To identify features of antinuclear antibody (ANA)-HEp-2 test results that discriminate ANA-positive healthy individuals and patients with autoimmune rheumatic diseases (ARDs).
  30. ncbi Self-management of rheumatic diseases: state of the art and future perspectives
    Maura D Iversen
    Correspondence to Professor Maura Daly Iversen, Department of Physical Therapy, Bouve College of Health Sciences, Northeastern University, 301 C Robinson Hall, 360 Huntington Avenue, Boston, MA 02115, USA
    Ann Rheum Dis 69:955-63. 2010
    ..This systematic review presents data from clinical studies of self-management over the past decade, summarises the evidence for programme effectiveness, and suggests future research directions...
  31. ncbi Pain, catastrophizing, and depression in the rheumatic diseases
    Robert R Edwards
    Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Women s Hospital, 850 Boylston Street, Suite 302, Chestnut Hill, MA 02467, USA
    Nat Rev Rheumatol 7:216-24. 2011
    ..depression and catastrophizing to the experience of pain and pain-related sequelae across a number of rheumatic diseases. Depression and catastrophizing are consistently associated with the reported severity of pain, sensitivity ..
  32. ncbi Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I
    Charles G Helmick
    CDC, Atlanta, Georgia 30341 3717, USA
    Arthritis Rheum 58:15-25. 2008
    ..A companion article (part II) addresses additional conditions...
  33. pmc MicroRNAs in systemic rheumatic diseases
    Angela Ceribelli
    Department of Oral Biology, University of Florida, 1395 Center Drive, Gainesville, Florida 32610 0424, USA
    Arthritis Res Ther 13:229. 2011
    ..nonmalignant diseases, and there is accumulating evidence also for an important role of miRNAs in systemic rheumatic diseases. Abnormal expression of miRNAs has been reported in autoimmune diseases, mainly in systemic lupus ..
  34. pmc Hepatic manifestations of autoimmune rheumatic diseases
    S Abraham
    Centre for Rheumatology, Bloomsbury Rheumatology Unit, Department of Medicine, University College, London, UK
    Ann Rheum Dis 63:123-9. 2004
    ..These diseases are rare and may occur concomitantly or serially. Clinicians must be aware of the possibility of liver disease so that it can be treated as soon as possible...
  35. pmc Clinical utility of the anti-CCP assay in patients with rheumatic diseases
    D M Lee
    Department of Medicine, Division of Rheumatology, Immunology and Allergy Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Ann Rheum Dis 62:870-4. 2003
    To determine the frequency of antibodies to cyclic citrullinated peptides (CCP) in a group of patients with a diversity of rheumatic diseases.
  36. ncbi Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial
    Kenneth G Saag
    University of Alabama at Birmingham
    Arthritis Rheum 60:3346-55. 2009
    ..To compare the bone anabolic drug teriparatide (20 microg/day) with the antiresorptive drug alendronate (10 mg/day) for treating glucocorticoid-induced osteoporosis (OP)...
  37. ncbi Stress and resilience in rheumatic diseases: a review and glimpse into the future
    Andrea W M Evers
    Department of Medical Psychology 840, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    Nat Rev Rheumatol 7:409-15. 2011
    ....
  38. pmc Ultrasound in the evaluation of enthesitis: status and perspectives
    Frédérique Gandjbakhch
    Rheumatology Department, Universite Paris 6 Pierre et Marie Curie, hôpital La Pitié Salpêtrière, APHP, 83 Boulevard de l hôpital 75013 Paris, France
    Arthritis Res Ther 13:R188. 2011
    ....
  39. ncbi Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing
    Ru Li
    Department of Rheumatology and Immunology, Peking University People s Hospital, 11 Xizhimen South St, Beijing 100044, China
    Rheumatology (Oxford) 51:721-9. 2012
    To investigate the prevalence of eight common rheumatic diseases in a large Chinese population.
  40. ncbi Malignancy as a comorbidity in rheumatic diseases
    Carl Turesson
    Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Rheumatology (Oxford) 52:5-14. 2013
    Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies...
  41. ncbi Protective autoantibodies in the rheumatic diseases: lessons for therapy
    Gregg J Silverman
    Laboratory of B Cell Immunobiology, Departments of Medicine and Pathology, NYU School of Medicine, Alexandria Center, Room 804, 450 East 29th Street, New York, NY 10016, USA gregg silverman nyumc org
    Nat Rev Rheumatol 9:291-300. 2013
    ..These antibodies can also suppress key signalling pathways in the innate immune system involved in the control and resolution of inflammatory responses to Toll-like receptor agonists and disease-associated IgG autoantibodies...
  42. ncbi Increased cardiovascular risk factors in different rheumatic diseases compared with the general population
    Inger L Meek
    Arthritis Center Twente, Twente University and Medisch Spectrum Twente, 7500KA Enschede, The Netherlands
    Rheumatology (Oxford) 52:210-6. 2013
    ..To study the prevalence of cardiovascular risk factors among patients attending a rheumatology outpatient clinic in comparison with the general population...
  43. ncbi Malignancies in autoimmune rheumatic diseases - a mini-review
    Zoltan Szekanecz
    Department of Rheumatology, Institute of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
    Gerontology 57:3-10. 2011
    ..Systemic inflammatory rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma or dermatomyositis, may increase ..
  44. ncbi Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases
    Jae Hoon Kim
    Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
    Semin Arthritis Rheum 42:424-32. 2013
    ..and agreement between QuantiFERON-tuberculosis (TB) gold in tube test (QFT-GIT) and tuberculin skin test (TST) according to underlying rheumatic diseases and to identify the influencing factors on discrepancies between the 2 tests.
  45. ncbi Psychological interventions for patients with rheumatic diseases and anxiety or depression
    Rinie Geenen
    Utrecht University, Department of Clinical and Health Psychology, Utrecht, The Netherlands
    Best Pract Res Clin Rheumatol 26:305-19. 2012
    The prevalence of clinical anxiety and clinical depression in rheumatic diseases is about twice the prevalence seen in the general population...
  46. ncbi Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies
    Joseph Keane
    St James s Hospital and Trinity College Dublin, Ireland
    Curr Opin Rheumatol 20:443-9. 2008
    ..Because reactivation of latent tuberculosis infection is preventable, new data have demonstrated that these agents can be made safer when the clinician addresses latent tuberculosis infection...
  47. ncbi Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases
    P P Sfikakis
    First Department of Propedeutic Medicine, Laikon Hospital, Athens University Medical School, Greece
    Clin Rheumatol 18:28-32. 1999
    ..The possible clinical value of quantitation of circulating P-selectin in patients with RA and SSc on the one hand, and L-selectin in patients with SLE on the other, should be investigated by prospective studies...
  48. ncbi Role of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in rheumatic diseases
    Li Xiu Zhu
    Department of Rheumatology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China
    Chin Med J (Engl) 125:3898-904. 2012
    ..This review discusses the role of the TWEAK-Fn14 axis in several rheumatic diseases and the potential therapeutic benefits of modulation of the TWEAK-Fn14 pathway.
  49. ncbi Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan
    Kuang Hui Yu
    Chang Gung Memorial Hospital and Chang Gung University, Tao Yuan, Taiwan
    Arthritis Care Res (Hoboken) 65:244-50. 2013
    The purpose of this study was to determine the prevalence, incidence, and mortality rates of autoimmune rheumatic diseases (ARDs) by using a population-based database.
  50. ncbi HLA-DRB1* alleles and temporomandibular joint erosion in patients with various rheumatic diseases
    L M J Helenius
    Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital, Helsinki, Finland
    Scand J Rheumatol 33:24-9. 2004
    To investigate the association between HLA antigens and temporomandibular joint (TMJ) erosion, salivary composition, and focal sialadenitis in patients with rheumatic diseases.
  51. ncbi Superiority of a high loading dose of cholecalciferol to correct hypovitaminosis d in patients with inflammatory/autoimmune rheumatic diseases
    Pier Paolo Sainaghi
    Internal Medicine and Rheumatology Unit, Department of Translational Medicine, Università del Piemonte Orientale A Avogadro and AOU Maggiore della Carità and the Interdisciplinary Research Center of Autoimmune Diseases IRCAD, Novara, Italy
    J Rheumatol 40:166-72. 2013
    To compare 3 different cholecalciferol supplementation regimens in patients with rheumatic diseases.
  52. ncbi The role of biosimilars in the treatment of rheumatic diseases
    Thomas Dorner
    CC12 Department of Medicine, Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Chariteplatz 1, Berlin 10117, Germany
    Ann Rheum Dis 72:322-8. 2013
    ..As biosimilars are now in randomised controlled trials for treatment of rheumatic diseases, rheumatologists face decisions regarding equipoise and will need to consider their clinical use versus ..
  53. pmc Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature
    Archana Jain
    Department of Medicine at School of Medicine, University of Alabama, Birmingham, AL, USA
    Immunotherapy 5:265-99. 2013
    A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed...
  54. ncbi Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy
    Roberta Priori
    Dipartimento di Medicina Interna e Specialita Mediche, Sapienza Universita di Roma, Italy
    Autoimmun Rev 12:1022-30. 2013
    ..Metabolomic analysis has been applied to several disorders: as far as rheumatic diseases are concerned, a few studies have focused on rheumatoid arthritis, spondyloarthritis, systemic lupus ..
  55. ncbi The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank
    Frederick Wolfe
    National Data Bank for Rheumatic Diseases, University of Kansas School of Medicine, 1035 N Emporia, Suite 288, Wichita, KS 67214, USA
    Rheumatology (Oxford) 50:16-24. 2011
    The National Data Bank (NDB) for rheumatic diseases is a patient-based multi-disease, multi-purpose rheumatic disease registry that has been used primarily to study patients with RA, SLE, FM and OA...
  56. ncbi The impact of health literacy on health-related quality of life (HRQoL) and utility assessment among patients with rheumatic diseases
    Xu Hao Zhang
    Department of Pharmacy, National University of Singapore, Singapore
    Value Health 12:S106-9. 2009
    The objective of this study was to investigate the impact of health literacy (HL) on health-related quality of life (HRQoL) and utility assessment among patients with rheumatic diseases.
  57. ncbi Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology
    Ingris Pelaez-Ballestas
    Rheumatology Department, Hospital General de Mexico, Mexico City, Mexico
    J Rheumatol Suppl 86:3-8. 2011
    To estimate the prevalence of musculoskeletal (MSK) disorders and to describe predicting variables associated with rheumatic diseases in 5 regions of México.
  58. ncbi Clinical, radiographic and MRI findings of the temporomandibular joint in patients with different rheumatic diseases
    L M J Helenius
    Departments of Oral and Maxillofacial Diseases, Helsinki University Hospital, Helsinki, Finland
    Int J Oral Maxillofac Surg 35:983-9. 2006
    ..this study was to investigate the condition of the temporomandibular joint (TMJ) in patients with different rheumatic diseases, and report correlations between the clinical, radiographic and magnetic resonance imaging (MRI) findings...
  59. ncbi Outcomes and organ dysfunctions of critically ill patients with systemic lupus erythematosus and other systemic rheumatic diseases
    O T Ranzani
    Unidade de Terapia Intensiva, Departamento de Emergencia, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Med Biol Res 44:1184-93. 2011
    ..of critically ill patients with systemic lupus erythematosus (SLE) with patients with other systemic rheumatic diseases (SRD). We studied 116 critically ill SRD patients, 59 SLE and 57 other-SRD patients...
  60. ncbi Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic diseases: myth or reality?
    Miguel A Gonzalez-Gay
    Arthritis Rheum 57:191-2. 2007
  61. ncbi Reuma.pt - the rheumatic diseases portuguese register
    H Canhao
    Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisboa e Serviço de Reumatologia e Doenças Ósseas Metabólicas do CHLN Hospital de Santa Maria, Portugal
    Acta Reumatol Port 36:45-56. 2011
    ..pt, the Rheumatic Diseases Portuguese Register from the Portuguese Society of Rheumatology (SPR), which includes rheumatic patients (..
  62. ncbi The prevalences of some rheumatic diseases in western Turkey: Havsa study
    Necati Cakir
    Division of Rheumatology, Medical Faculty, Trakya University, Edirne, Turkey
    Rheumatol Int 32:895-908. 2012
    To study the prevalence major rheumatic diseases in western Turkey. This survey was conducted in Havsa which have a total population of 18,771...
  63. ncbi EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
    N Duru
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
    Ann Rheum Dis 72:1905-13. 2013
    ..5 mg but ≤100 mg prednisone equivalent daily) systemic glucocorticoid (GC) therapy in rheumatic diseases. A multidisciplinary EULAR task force was formed, including rheumatic patients...
  64. ncbi What can we learn from epigenetics in the year 2009?
    Astrid Jungel
    Center of Experimental Rheumatology, University Hospital and Zurich Center of Integrative Human Physiology, Switzerland
    Curr Opin Rheumatol 22:284-92. 2010
    ..Even though current therapies with biologics such as tumor necrosis factor-alpha blockers yield significant improvement for the patients, the disease is not curable yet. Therefore, we need novel strategies for better therapies...
  65. ncbi Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections
    Daniel Tesfa
    Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Arthritis Rheum 63:2209-14. 2011
    ..The purpose of this study was to define the incidence, clinical features, and some of the underlying mechanisms of late-onset neutropenia in relation to rituximab use in several rheumatic diseases.
  66. ncbi Oxidative stress parameters in different systemic rheumatic diseases
    Omidreza Firuzi
    Dipartimento di Fisiologia Umana e Farmacologia Vittorio Erspamer, Universita di Roma La Sapienza, Italy
    J Pharm Pharmacol 58:951-7. 2006
    ..21 +/- 1.0 nmol (mg protein)(-1); P < 0.05). The obtained data indicate augmented free radical-mediated injury in these rheumatic diseases and suggest a role for the use of antioxidants in prevention and treatment of these pathologies.
  67. ncbi CD4+CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases
    Jocea M R Michels-van Amelsfort
    Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Expert Rev Clin Immunol 7:499-514. 2011
    ..Here, we will review recent data on the percentage, function and phenotype of CD4(+)CD25(+) Tregs in rheumatic disease, and discuss how recent developments may guide research in this area in SSc...
  68. ncbi The role of spa therapy in various rheumatic diseases
    S Sukenik
    Department D, Soroka University Hospital, Beer Sheva, Israel
    Rheum Dis Clin North Am 25:883-97. 1999
    ..Because we have no way to date, of curing most rheumatic diseases, clinical trials of alternative therapeutic methods are justified...
  69. ncbi Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases
    Marc Humbert
    Center for Pulmonary Vascular Diseases, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, France
    Nat Clin Pract Rheumatol 1:93-101. 2005
    ..Canada, and Europe, for treatment of pulmonary arterial hypertension (PAH), including PAH associated with rheumatic diseases. ERAs with specificity for the endothelin-receptor subtype A, including sitaxsentan and ambrisentan, are ..
  70. ncbi Rheumatologic manifestations of chronic hepatitis C infection
    Christian Lormeau
    Rheumatology Department and INSERM ERI 18, Avicenne Teaching Hospital AH HP and Paris 13 University, 125, rue de Stalingrad, 93009 Bobigny, France
    Joint Bone Spine 73:633-8. 2006
    ..Other conditions reported in patients with chronic HCV infection include fibromyalgia, systemic lupus erythematosus (SLE), antiphospholipid syndrome, and osteosclerosis...
  71. ncbi Smoking as a trigger for inflammatory rheumatic diseases
    Lars Klareskog
    Rheumatology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Solna, Stockholm, Sweden
    Curr Opin Rheumatol 19:49-54. 2007
    ..has two purposes: to describe the known effects of cigarette smoking on the development of inflammatory rheumatic diseases, in particular rheumatoid arthritis and systemic lupus erythematosus, and to review recent research aimed at ..
  72. ncbi [Evaluation of inpatient naturopathic treatment--the Blankenstein model. Part II: Effective strength and health status of patients over the course of time]
    T Ostermann
    Lehrstuhl für Medizintheorie und Komplementärmedizin der Fakultät für Medizin, Universitat Witten Herdecke, Germany
    Forsch Komplementarmed Klass Naturheilkd 9:269-76. 2002
    ..For a period of 3 years (starting on July 1,1999) it has been scientifically accompanied by the Chair of Medical Theory and Complementary Medicine at the University of Witten/ Herdecke...
  73. pmc PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it
    N Ruperto
    Paediatric Rheumatology INternational Trials Organisation PRINTO, IRCCS G Gaslini, Pediatria II Reumatologia, Largo Gaslini, 5, 16147 Genova, Italy
    Ann Rheum Dis 64:1101-6. 2005
    To prepare a website for families and health professionals containing up to date information about paediatric rheumatic diseases (PRD).
  74. ncbi Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach
    Erika Rodrigues Senna
    Department of Medicine, University of Montes Claros UNIMONTES, Sao Paulo, Brazil
    J Rheumatol 31:594-7. 2004
    To estimate the prevalence of rheumatic diseases in residents of Montes Claros, Brazil, of both sexes, aged above 16 years, using the COPCORD questionnaire.
  75. ncbi Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases
    Michael Mahler
    Department of Research, INOVA Diagnostics Inc, San Diego, California, USA
    J Rheumatol 39:2104-10. 2012
    Antinuclear antibodies (ANA) are a serological hallmark of systemic autoimmune rheumatic diseases (SARD) such as systemic lupus erythematosus (SLE)...
  76. ncbi Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Claudio Galarza
    Unidad de Enfermedades Reumáticas y Autoinmunes UNERA, Hospital Monte Sinai, Cuenca, Guayaquil, Ecuador
    Clin Rev Allergy Immunol 34:124-8. 2008
    ..monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD)...
  77. ncbi Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases
    Lisa K Stamp
    Department of Biochemistry, University of Otago, Dunedin 9054, New Zealand
    Pharmacogenomics 12:1449-63. 2011
    ..Prospective studies, standardizing the definitions of response and toxicity, and application of genome-wide approaches may advance the search for genetic predictors of MTX response...
  78. ncbi Evidence for prescribing exercise as treatment in pediatric rheumatic diseases
    Bruno Gualano
    Universidade de Sao Paulo, School of Physical Education and Sports, Brazil
    Autoimmun Rev 9:569-73. 2010
    ..that impair the health-related quality of life and functional capacity of children and adolescents with rheumatic diseases. Interestingly, cumulative evidence has suggested that exercise training may benefit patients with juvenile ..
  79. pmc Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases
    Sherine E Gabriel
    Department of Health Sciences Research, Mayo Foundation, Rochester, MN 55905, USA
    Arthritis Res Ther 11:229. 2009
    ..comorbidity, mortality, trends over time, geographic distributions, and clinical characteristics) of the rheumatic diseases. This progress is reviewed for the following major rheumatic diseases: rheumatoid arthritis (RA), juvenile ..
  80. ncbi Validity and reliability of the EQ-5D self-report questionnaire in Chinese-speaking patients with rheumatic diseases in Singapore
    N Luo
    Department of Pharmacy, National University of Singapore NUS
    Ann Acad Med Singapore 32:685-90. 2003
    ..We assessed the psychometric properties of a Singaporean Chinese version of the EQ-5D, a health-related quality of life (HRQoL) instrument...
  81. ncbi Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheuma
    S van Assen
    Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands
    Autoimmun Rev 10:341-52. 2011
    ..the systematic literature review (SLR), which formed the basis for the European League Against Rheumatism (EULAR) evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases (AIIRD).
  82. ncbi Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases
    Alan Tyndall
    Department of Rheumatology, Felix Platter Spital, University of Basel, Basel, Switzerland
    Pediatr Res 71:433-8. 2012
    ..Despite encouraging small phase I/II studies, no positive data from randomized, prospective studies are as yet available in the peer-reviewed literature...
  83. ncbi Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases
    Andrea T Borchers
    Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, CA 95616, USA
    J Autoimmun 37:273-88. 2011
    Biological agents represent a major advance in the treatment of rheumatic diseases, most particularly in the prevention of irreversible structural damage...
  84. pmc Factors promoting health-related quality of life in people with rheumatic diseases: a 12 month longitudinal study
    Susann Arvidsson
    Research and Development Centre Spenshult, Spenshult Hospital for Rheumatic Diseases, Oskarström, Sweden
    BMC Musculoskelet Disord 12:102. 2011
    b>Rheumatic diseases have a significant adverse impact on the individual from physical, mental and social aspects, resulting in a low health-related quality of life (HRQL)...
  85. ncbi Intravenous immunoglobulin therapy in rheumatic diseases
    Jagadeesh Bayry
    Institut National de Santé et de Recherche Médicale Unité 872 INSERM U872, Université Pierre et Marie Curie and Université René Descartes, 15 Rue de l Ecole de Medicine, Paris, F 75006, France
    Nat Rev Rheumatol 7:349-59. 2011
    ..However, dosage regimens have not been thoroughly explored, and indications for IVIg in most rheumatic diseases, such as systemic lupus erythematosus, polymyositis and catastrophic antiphospholipid syndrome, derive from ..
  86. pmc Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases
    R L Wilder
    Clinical Development, MedImmune, Inc, 35 W Watkins Mill Road, Gaithersburg, MD 20878, USA
    Ann Rheum Dis 61:ii96-9. 2002
    ..It blocks the interaction of alpha V beta 3 with various ligands such as osteopontin and vitronectin. Clinical trials with Vitaxin in patients with RA are in progress...
  87. ncbi Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases
    Junko Maruyama
    Department of Allergy and Immunological Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    J Rheumatol 37:967-73. 2010
    To elucidate the cytokine profiles of macrophage activation syndrome (MAS) in relation to underlying rheumatic diseases and prognosis.
  88. ncbi The impact of rheumatic diseases on sexual function
    Antonio G Tristano
    Instituto Medico La Floresta, Caracas, Venezuela
    Rheumatol Int 29:853-60. 2009
    ..b>Rheumatic diseases may affect all aspects of life including sexual functioning...
  89. ncbi Possible pathogenic nature of the recently discovered TT virus: does it play a role in autoimmune rheumatic diseases?
    Peter Gergely
    National Institute of Rheumatology and Physiotherapy, Frankel Leó u 38 40, H 1023 Budapest, Hungary
    Autoimmun Rev 6:5-9. 2006
    Pathogenesis of viral origin has long been suggested in autoimmune rheumatic diseases. Beside the well-defined virus induced transient or chronic rheumatic diseases often resembling systemic autoimmune disorders such as rheumatoid ..
  90. ncbi Frequency of rheumatic diseases in patients with autoimmune thyroid disease
    Mehmet Soy
    Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, 22300, Edirne, Turkey
    Rheumatol Int 27:575-7. 2007
    We aimed to investigate the frequency of rheumatic diseases in patients suffering from autoimmune thyroid diseases (ATD)...
  91. pmc MicroRNAs as biomarkers in rheumatic diseases
    Ilias Alevizos
    Sjögren s Syndrome Clinic, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, 10 Center Drive, 1N110, Bethesda, MD 20892, USA
    Nat Rev Rheumatol 6:391-8. 2010
    ..There is accumulating evidence that miRNAs have an important role in systemic rheumatic diseases and that various diseases or different stages of the same disease are associated with distinct miRNA ..
  92. ncbi Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma
    Catarina Dias
    Internal Medicine Department, Funchal Central Hospital, Estrada dos Marmeleiros, 9054 535 Funchal, Madeira Island, Portugal
    Nat Rev Rheumatol 7:360-8. 2011
    Autoimmune rheumatic diseases (ARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's syndrome (SS), have consistently been associated with the development of B-cell non-Hodgkin lymphoma (BCNHL)...
  93. ncbi Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases
    Antonio Fernandez-Nebro
    Servicio de Reumatología y Departamento de Medicina de la Facultad de Medicina, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Am J Med 123:454-61. 2010
    ..To evaluate the effectiveness and safety of anti-tumor necrosis factor therapy in patients with amyloid A amyloidosis...
  94. ncbi New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases
    Daniel Wendling
    Department of Rheumatology, Université de Franche Comté EA 4266, Centre Hospitalier Universitaire, Besancon, France
    Semin Arthritis Rheum 41:503-10. 2011
    ..Under these circumstances, de novo occurrence, ie, new onset of the first episode of uveitis under anti-TNF therapy, is uncommon...
  95. ncbi Sensors of the innate immune system: their link to rheumatic diseases
    Argyrios N Theofilopoulos
    Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Nat Rev Rheumatol 6:146-56. 2010
    ..intracellular innate immune receptors is central to the pathogenesis of most autoimmune and autoinflammatory rheumatic diseases. The initiation of aberrant innate and adaptive immune responses in autoimmune diseases can be triggered by ..
  96. ncbi A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care
    Theodore Pincus
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    Bull NYU Hosp Jt Dis 65:150-60. 2007
    b>Rheumatic diseases differ from many chronic diseases in that no single measure provides a gold standard for diagnosis, prognosis, monitoring, and documentation of changes over long periods...
  97. pmc Tissue engineering in the rheumatic diseases
    Jochen Ringe
    Tissue Engineering Laboratory and Berlin Brandenburg Center for Regenerative Therapies, Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Tucholskystr 2, 10117 Berlin, Germany
    Arthritis Res Ther 11:211. 2009
    ..activity, these cells are prominent candidates for future tissue engineering approaches for the treatment of rheumatic diseases. Tissue engineering also provides highly organized three-dimensional in vitro culture models of human cells ..
  98. ncbi Classification criteria in rheumatic diseases: a review of methodologic properties
    Sindhu R Johnson
    University Health Network, Toronto, Ontario, Canada
    Arthritis Rheum 57:1119-33. 2007
    To identify classification criteria for the rheumatic diseases and to evaluate their measurement properties and methodologic rigor using current measurement standards.
  99. ncbi AUF1, the regulator of tumor necrosis factor alpha messenger RNA decay, is targeted by autoantibodies of patients with systemic rheumatic diseases
    Karl Skriner
    Department of Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Germany
    Arthritis Rheum 58:511-20. 2008
    To investigate which members of the heterogeneous nuclear RNP (hnRNP) family are targeted by autoantibodies from patients with systemic rheumatic diseases.
  100. ncbi Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy
    F Kanakoudi-Tsakalidou
    A Department of Pediatrics, Influenza Reference Center, Aristotle University, Thessaloniki, Greece
    Clin Exp Rheumatol 19:589-94. 2001
    To study the immunogenicity, safety and efficacy of influenza vaccine in children with chronic rheumatic diseases (CRD) receiving long-term immunosuppressive therapy.
  101. pmc Tai chi and rheumatic diseases
    Chenchen Wang
    Division of Rheumatology, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Box 406, Boston, MA 02111, USA
    Rheum Dis Clin North Am 37:19-32. 2011
    ..This article overviews the current knowledge about tai chi to better inform clinical decision making for rheumatic patients...

Research Grants73

  1. Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis
    Shervin Assassi; Fiscal Year: 2013
    ..expertise with a goal of applying for NIH R01 Award, focusing on identification of predictive biomarkers in rheumatic diseases and examination of their clinical usefulness in prospective studies...
  2. Comparative Effectiveness Research in Pediatric Rheumatic Diseases: Leveraging CA
    CAROL A contact WALLACE; Fiscal Year: 2010
    ..The long-term goal is to improve the health related outcomes of children with rheumatic diseases by entering children into treatment protocols and registries which will enable in and of itself improve care,..
  3. A rational approach to liver toxicity monitoring in methotrexate users
    Gabriela Schmajuk; Fiscal Year: 2013
    ..to improve patient safety, reduce unintended harms, and maximize the quality of care for patients with rheumatic diseases. Aims 1 and 2 of this proposal will leverage administrative and clinical data from the Veterans Affairs ..
  4. Body composition, bone structure, and joint damage in rheumatoid arthritis
    Joshua F Baker; Fiscal Year: 2013
    ..with advanced training in clinical epidemiology and a focus on patient-oriented research in chronic rheumatic diseases. He has a long history of clinical work within the Philadelphia VA and has recently been appointed here as ..
  5. Yale Autoimmunity Center of Excellence
    Kevan C Herold; Fiscal Year: 2013
    ..Three clinical areas are involved: Rheumatic diseases (primary Sj"gren's syndrome (pSS)), Type 1 diabetes (T1DM), and inflammatory bowel disease (IBD)...
  6. Mac-1 (CR3) and Fc gamma receptors in immune-mediated neutrophil cytotoxicity
    Tanya N Mayadas; Fiscal Year: 2013
    ..For example, the inflammatory destruction of the vessel wall, vasculitis, is observed in autoimmune rheumatic diseases with cutaneous involvement being the most common, and neutrophil accumulation being a common feature...
  7. Antibody cytokine fusion proteins against Cryptococcus neoformans
    DAVID OWEN BEENHOUWER; Fiscal Year: 2012
    ..number of persons with immunocompromise due to immuno- suppressive therapies for organ transplantation and rheumatic diseases as well as chemotherapy for cancer...
  8. Proteomic Identification of Actionable Biomarkers in Rheumatoid Arthritis
    William H Robinson; Fiscal Year: 2010
    ..specific Challenge Topic, 03-AR-103 Biomarkers: Bench to Bedside for Autoimmune and Inflammatory Skin and Rheumatic Diseases. Title: Proteomic Identification of Actionable Biomarkers in Rheumatoid Arthritis Project Summary/Abstract ..
  9. Caspase 8: A Novel Suppressor of Dendritic Cell-Mediated Autoimmunity
    Carla M Cuda; Fiscal Year: 2013
    ..Uncovering novel mechanistic pathways involved in immune cell-mediated pathogenesis of autoimmune rheumatic diseases has been a consistent theme throughout my research career...
  10. RANKL and Inflammation-associated Bone Loss
    CHARLES A O'BRIEN; Fiscal Year: 2012
    ..and especially adjacent to inflamed joints, is a major cause of morbidity and fracture in veterans with rheumatic diseases. Although bisphosphonates are sometimes used to protect bone in veterans with rheumatoid arthritis, there is ..
  11. B cell metabolism in activation and autoantibody production
    Jeffrey C Rathmell; Fiscal Year: 2013
    ..To test this new direction for treatment of rheumatic diseases, it is essential to understand B cell metabolism and how changes in metabolism impact B cell tolerance and ..
  12. Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.
    SEOYOUNG CATHERINE KIM; Fiscal Year: 2013
    ..Allergy at Brigham and Women's Hospital (BWH), undertaking a training in Pharmacoepidemiology in the rheumatic diseases under the guidance of Drs. Daniel H. Solomon and Sebastian Schneeweiss...
  13. Collider Bias and the Risk Factor Paradoxes in Rheumatic Disease Research
    UYEN SA DUC TRAN NGUYEN; Fiscal Year: 2013
    ..associated with assessing the risk conferred by purported risk factors for sequela events among people with rheumatic diseases, we will investigate paradoxical findings in 3 key rheumatic disease contexts (smoking and risk of CV events ..
  14. Role of BH3-domain proteins in the effector phase of RA
    HARRIS R PERLMAN; Fiscal Year: 2012
    ..These studies are the first to show the efficacy of BH3 peptides as a potential molecule for treatment of RA. Our immediate goal is to develop the BH3 peptide therapy as a front line treatment for RA and other rheumatic diseases.
  15. RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease
    WILLIAM J MC CUNE; Fiscal Year: 2012
    ..ovarian injury versus placebo in women of reproductive age being treated with cyclophosphamide for severe rheumatic diseases. Women ages 18-40 years who require administration of daily oral or intermittent pulse cyclophosphamide ..
  16. Training Grant in Inflammatory and Fibrosing Diseases
    Gary S Gilkeson; Fiscal Year: 2013
    ..patients from the Southeastern United States, emphasizing research and care of African Americans with rheumatic diseases. Our training program emphasizes the interrelationship between inflammation and fibrosis and the impact of ..
  17. Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
    Michel Ledizet; Fiscal Year: 2012
    ..burgdorferi, and other infectious and rheumatic diseases. Peptide pin arrays will map the immunodominant epitopes of candidate antigens with Lyme disease sera in an ..
  18. Outcomes Research in Rheumatic Diseases
    Dinesh Khanna; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Outcomes research in rheumatic diseases The goals of the K24 application are to support my continued development and impact as a mentor, to establish a research training program for patient-oriented ..
  19. IMMUNOLOGIC/GENETIC MECHANICSMS IN RHEUMATIC DISEASES
    Westley H Reeves; Fiscal Year: 2013
    ..program is to provide a broad investigational experience in laboratory or non-laboratory research related to rheumatic diseases. The Program focuses on autoimmunity and the connective tissue diseases...
  20. MCRC for Rheumatic Diseases in African Americans
    Gary S Gilkeson; Fiscal Year: 2013
    ..or who are at risk of developing, systemic lupus erythematosus, systemic sclerosis, and other debilitating rheumatic diseases. The Center is built on a solid framework of strong leadership in Rheumatology, Biostatistics and Health ..
  21. Family History, Genes, Environment and G X E Interaction in Predicting RA Risk
    Elizabeth W Karlson; Fiscal Year: 2013
    ..Maintain and expand my clinical research training program by mentoring new clinical investigators in POR in rheumatic diseases;2) Enrich my comprehensive POR program to study family history, genetic, and environmental predictors in the ..
  22. Mechanisms by which IL-10 limits Toll-like Receptor 9 mediated Macrophage Activat
    Scott Canna; Fiscal Year: 2012
    ..MAS) is an uncommon but potentially life-threatening complication of many infectious, malignant and rheumatic diseases. It is characterized by fever, difficulty clotting and multiple organ dysfunctio in the setting of ..
  23. Suppression of MMP-13 Expression in Arthritis by Pomegranate
    Tariq M Haqqi; Fiscal Year: 2013
    ..Specific miRNAs has been shown to exhibit altered pattern of expression in RA synovium and in other rheumatic diseases but their role in OA pathogenesis is yet to be defined...
  24. The Role of Gut and Skin Microbiome in Psoriatic Arthritis
    Jose U Scher; Fiscal Year: 2013
    ..career goal is to become an independent academic research scientist working at the interface between rheumatic diseases, immunology, microbiology, and computational analytics in the area of causal discovery methods...
  25. Cancer risk after renal transplant in autoimmune disease
    Rosalind Ramsey-Goldman; Fiscal Year: 2013
    ..The literature also highlights a very similar cancer risk profile in several autoimmune rheumatic diseases, including systemic lupus erythematosus (SLE)...
  26. ACR Basic Research Conference
    Bruce Neil Cronstein; Fiscal Year: 2013
    ..the bidirectional exchange of cutting edge scientific information between scientists and investigators in rheumatic diseases through its annual Basic Research Conference, a scientific symposium that occurs immediately prior to the ..
  27. Targeting TAM Receptors to Modulate Inflammation and Autoimmunity
    Philip L Cohen; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Control of inflammation is central to the treatment of most rheumatic diseases and of many other illnesses encountered throughout medicine...
  28. Systems Biology of Psoriasis
    Weixiong Zhang; Fiscal Year: 2010
    ..Area (06) Enabling Technologies and specific Challenge Topic: 06-AR-103, Systems Biology for Skin and Rheumatic Diseases. Psoriasis (PS) is a complex inflammatory skin disease where genetic risk factors and environmental trigger ..
  29. Defining Microbial and Host Factors in Innate Immune Responses in Lyme Arthritis
    Klemen Strle; Fiscal Year: 2013
    ..Macrophages are also implicated in the pathogenesis of other rheumatic diseases including RA in which the synovial lesions are similar to those in patients with antibiotic-refractory Lyme ..
  30. Genetic Architecture of Rheumatoid Arthritis in African-Americans
    MARIA IOANA DANILA; Fiscal Year: 2013
    ..The applicant's career goal is to become an independently funded investigator in the genetics of rheumatic diseases, particularly rheumatoid arthritis (RA)...
  31. CARRA: Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology
    Carol A Wallace; Fiscal Year: 2010
    ..global acceptance of evidence-based protocol-driven care as the optimal approach to treatment of pediatric rheumatic diseases by families, patients, and health care providers...
  32. Proteomic Analyses of Pediatric Systemic Lupus Erythematosus
    IMELDA MARIE BALBONI; Fiscal Year: 2013
    ..rheumatology and translational research in the field of autoimmunity, with a particular focus on pediatric rheumatic diseases, including pediatric systemic lupus erythematosus (pSLE)...
  33. Identifying Vulnerable Plaque in Rheumatoid Arthritis
    Kimberly P Liang; Fiscal Year: 2013
    ..has a strong track record of presenting and publishing work in the areas of premature atherosclerosis in the rheumatic diseases as well as in vasculitis...
  34. Cadherin-11 Regulation of Fibroblast-like Synoviocytes in Synovial Inflammation
    Sandeep K Agarwal; Fiscal Year: 2012
    ..is to become an investigator in an academic medical center performing basic and translational research of rheumatic diseases. Building on my previous experiences, I herein propose a comprehensive career development plan that combines ..
  35. Rheumatic Disease Sera: Probes of Disease Mechanisms
    Livia A Casciola-Rosen; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): The causes and mechanisms of many autoimmune rheumatic diseases remain obscure, and therapy largely remains empirical and non-specific...
  36. Clinical and Cost-effectiveness of biologics in Rheumatoid Arthritis
    Hyon K Choi; Fiscal Year: 2010
    ..we will perform a systematic literature review and analyze three large RA registries (National Data Bank for Rheumatic Diseases [n=25,977]), Swedish RA registry [n=40,000], and RA Investigational Network [n=2,000]) to compare the ..
  37. TRAINING OF ARTHRITIS RESEARCH SCIENTISTS
    DAVID ALAN FOX; Fiscal Year: 2013
    ..for careers as independent investigators in basic, translational or clinical research in systemic rheumatic diseases. The proposed Training Program Director is Dr...
  38. Exercise and Depression in Adults with Arthritis: An IPD Meta-Analysis
    George A Kelley; Fiscal Year: 2013
    ..compared to healthy controls, depressive symptoms are more prevalent among adults with arthritis and other rheumatic diseases (AORD)...
  39. Enhancing the CARRA: Integration and Dissemination of Clinical Data
    Laura E Schanberg; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The CARRA Rheumatic Diseases Core Center (CARRA-RDCC) requests funding for expansion of the clinical and translational research mission of the Childhood Arthritis and Rheumatology Research Alliance (..
  40. T cell response in scleroderma lung disease: from pathogenesis to clinical care
    Francesco Boin; Fiscal Year: 2012
    ..award is to acquire the skills and expertise to become an independent investigator in the field of rheumatic diseases. This will occur through a period of intense didactic and research training in the Division of Rheumatology ..
  41. Pathogenesis of autoimmune myositis: Role of MHC Class 1
    Kanneboyina Nagaraju; Fiscal Year: 2009
    Specific therapies are not currently available for systemic autoimmune rheumatic diseases. Development of specific and effective therapies requires the definition of pathways important in the disease pathogcncsis...
  42. Predictors and Consequences of Subchondral Bone Attrition in Osteoarthritis
    Tuhina Neogi; Fiscal Year: 2011
    ..in an academic position as a clinician scientist, with a research career focused on epidemiologic study of rheumatic diseases. At present, my interests lie in studying pathophysiologic contributors to osteoarthritis (OA), and in ..
  43. HEART DISEASE IN RHEUMATOID ARTHRITIS
    Sherine E Gabriel; Fiscal Year: 2013
    ..external validation will be conducted using the large (n=25,977) and well established National Databank for Rheumatic Diseases. The creation of effective CV risk prediction tools and biomarkers will enable targeting of screening and ..
  44. INTEGRIN-DEPENDENT T CELL-MEDIATED MECHANISMS OF PULMONARY FIBROSIS
    Irina G Luzina; Fiscal Year: 2010
    ..by applicant): Pulmonary fibrosis is a major cause of disability and death in patients with autoimmune rheumatic diseases such as scleroderma, rheumatoid arthritis, dermatomyositis and polymyositis...
  45. Training grant in Rheumatic Diseases
    GARY STEVEN FIRESTEIN; Fiscal Year: 2010
    ..program is designed to train physicians and scientists interested in biomedical research in the area of rheumatic diseases. The training program will consist of either 1) a laboratory experience under the close supervision of a ..
  46. Rheumatic Diseases Research Training Grant
    Robert A Terkeltaub; Fiscal Year: 2013
    ..at the level of MDs, MD/PhDs, and PhD scientists, interested in biomedical research in the area of rheumatic diseases. The training program will consist of a bench research laboratory experience of 12-36 months, under the ..
  47. Impact of Rheumatologist Communication Upon Managing Cardiovascular Risk in RA
    Christie Michels Bartels; Fiscal Year: 2013
    ..independent research program to improve the cardiovascular health and survival of patients with inflammatory rheumatic diseases. She proposes a 3-year K23 period with training in advanced statistics, barrier analysis, and translational ..
  48. Vanderbilt Multidisciplinary Clinical Research Center
    Charles M Stein; Fiscal Year: 2012
    ..a multidisciplinary clinical research scientific program that will alter the outcomes of patients with rheumatic diseases. 2) To promote and foster multidisciplinary clinical research in rheumatic diseases by leveraging ..
  49. Research Training in Rheumatology at Massachusetts General Hospital
    Andrew D Luster; Fiscal Year: 2012
    ..of particular interest include leukocyte trafficking, chemokine and integrin biology, infectious causes of rheumatic diseases, and the link between inflammation and bone disease...
  50. Rheumatic Diseases Research Core Centers
    ROBERT A LAFYATIS; Fiscal Year: 2013
    ..In addition, the common platform and clinical data collected across cores will provide a large, common database for understanding clinical-pathological associations. ..
  51. Oklahoma Rheumatic Disease Research Cores Center
    Judith A James; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The Oklahoma Rheumatic Diseases Research Cores Center (ORDRCC) currently supports rheumatic disease research for 32 junior ORDRCC investigators (some from outside Oklahoma) and 16 senior Center ..
  52. RESEARCH TRAINING IN RHEUMATOLOGY
    VERNON MICHAEL HOLERS; Fiscal Year: 2013
    ..goal of this T32 program is to provide outstanding research training in the pathogenesis and treatment of rheumatic diseases for individuals at several key levels of career development (medical and doctoral graduate students, ..
  53. Cancer Risk in Pediatric-Onset Rheumatic Disease
    SASHA RUTH BERNATSKY; Fiscal Year: 2012
    ..In adults, there is evidence of increased cancer risk in several autoimmune rheumatic diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)...
  54. Long-term Comparative Effectiveness of Rheumatoid Arthritis Treatment Strategies
    HAWRE JALAL; Fiscal Year: 2011
    ..3) incorporating long-term treatment sequences from the National Databank of Rheumatic Diseases (NDB) is a major proposed improvement in this study...
  55. Glucocorticoid Regimens and Cardiovascular Risk
    Steven C Vlad; Fiscal Year: 2013
    ..as an independent researcher in the field of pharmacoepidemiology with special interest in drugs used in the rheumatic diseases. The increasing availability of extremely large patient-care databases with comprehensive clinical ..
  56. ACR Clinical Research Conference
    Bruce Neil Cronstein; Fiscal Year: 2013
    ..cultivated an environment for the exchange of cutting edge scientific information between investigators in rheumatic diseases and clinicians through its annual Clinical Research Conference, a scientific symposium that occurs ..
  57. NUCLEAR ACIDIC PROTEIN ANTIGENS IN RHEUMATIC DISEASES
    GORDON SHARP; Fiscal Year: 1990
    The objective is to elucidate the roles of nuclear acidic protein antigens and certain other antigens in rheumatic diseases and in basic cellular biology...
  58. IMMUNOLOGIC MECHANISMS AND RHEUMATIC DISEASE
    Michael B Brenner; Fiscal Year: 2013
    ..of cellular and molecular biology, genetics, and fundamental studies of immunology and bone biology of rheumatic diseases. Original population-based clinical research employs rigorous methodological design and statistical analysis...
  59. Pediatric Rheumatology Research Annual Scientific Meeting
    CHRISTY IRENE SANDBORG; Fiscal Year: 2013
    ..epigenetic and inflammatory), epidemiology, and current and innovative therapeutic approaches in pediatric rheumatic diseases;2...
  60. Mechanisms of Alteration of B Lymphocyte Function by LMP1
    Gail A Bishop; Fiscal Year: 2013
    ..re-expressed in people whose immune systems are seriously suppressed, as well as in disease flares of rheumatic diseases. LMP1 has been associated with exacerbating autoimmune diseases and B cell malignancies, due to its ability ..
  61. NIAMS MULTIDISCIPLINARY CLINICAL RESEARCH CENTER
    Leena Sharma; Fiscal Year: 2013
    ..Research Center (MCRC) are to: 1) conduct cutting-edge research aimed at the prevention or control of rheumatic diseases and poor outcomes associated with these conditions;2) provide the academic environment that a) supports the ..
  62. Cancer, Autoantigens, and Scleroderma Investigating the Connection
    AMI AALOK SHAH; Fiscal Year: 2013
    ..over 4800 subjects;the Bayview Biostatistics, Epidemiology and Data Management (BEAD) Core;the Johns Hopkins Division of Oncology;and the Rheumatic Diseases Research Core Center (RDRCC) are fully available to make this project a success.
  63. Cincinnati Multidisciplinary Clinical Research Center
    DANIEL JOE LOVELL; Fiscal Year: 2012
    ..P60 Multidisciplinary Clinical Research Center grant and is complementary to our ongoing P30 Cincinnati Rheumatic Diseases Core Center grant...
  64. B27 BINDING BACTERIAL AND SELF PEPTIDES IN B27 ARTHRITIS
    R Scofield; Fiscal Year: 2000
    DESCRIPTION (Adapted from the applicant's Abstract): The spondyloarthropathies are a group of chronic rheumatic diseases of unknown etiology...
  65. ETHNIC DISPARITY IN THE USE OF JOINT ARTHROPLASTY
    DENNIS ANG; Fiscal Year: 2007
    ..It is the mission of the Center to pursue major biomedical research interests relevant to the rheumatic diseases. Most recently, the center became the lead institution in a clinical study of doxycycline and its ability to ..
  66. ARTICULAR CARTILAGE REPAIR
    Robert Sah; Fiscal Year: 1999
    ..of cartilage-cartilage or cartilage-tissue interfaces, is required in a number of orthopaedic conditions and rheumatic diseases including osteochondral fractures, osteochondritis dissecans, and osteoarthritis, as well as in articular ..
  67. INTERNATIONAL CONFERENCE ON RHEUMATIC DISEASES PREGNANCY
    Jill Buyon; Fiscal Year: 1992
    ..from the applicant's abstract) In recent years there has been an increasing interest in pregnancy and rheumatic diseases, with pursuits in basic research as well as clinical investigation...
  68. MULTIPURPOSE ARTHRITIS & MUSCULOSKELETAL DISEASE CENTER
    HARRY BLUESTEIN; Fiscal Year: 2000
    ..The Center brings together medical and health services research activities in rheumatic diseases at four institutions in the San Diego area: the University of California, San Diego, The Scripps Research ..
  69. Genetics of Severe Systemic Lupus Erythematosus (SLE) defined by thrombocytopenia
    R Scofield; Fiscal Year: 2007
    ..Research is an experienced and productive physician-scientist whose work has concentrated upon autoimmune rheumatic diseases, including systemic lupus erythematosus...
  70. REGULATION OF GLUCOSE TRANSPORT BY CTAP-III ISOFORMS
    Christin Carter Su; Fiscal Year: 1993
    ..increased secretion of extracellular matrix and increased replication of connective tissue cells in rheumatic diseases. One such peptide, CTAP-III (connective tissue activating peptide-III), is a member of a family of ..
  71. NUCLEAR PROTEINS AND AUTOIMMUNITY
    SALLIE HOCH; Fiscal Year: 1992
    ..research is directed toward the characterization of the nuclear proteins that serve as indicators of various rheumatic diseases, including systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)...
  72. REGULATION OF COLLAGENASE 3 GENE EXPRESSION BY CYTOKINES
    Mahboob Rahman; Fiscal Year: 2002
    ..in order to better understand the mechanisms involved in the degradation of articular cartilage in rheumatic diseases such as rheumatoid arthritis (RA) and osteoarthritis ( OA)...
  73. The Relationship of n-3 Fatty Acids with Pain and Synovium in knee OA
    Kristin Baker; Fiscal Year: 2009
    ..and analyze studies on the therapeutic benefit of nutrition and exercise in the treatment and prevention of rheumatic diseases. I bring to my current research goals a unique background of training in measurement of physiologic ..